arrow
R

Renzo Manara

University-Hospital of Padova
H指数:44
被引数:6,904

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preoperative brain injury and neurodevelopmental outcomes in syndromic and non-syndromic children with complex congenital heart disease: a single-centre cohort study

术前脑损伤及神经发育结局在综合征性和非综合征性复杂先天性心脏病儿童中的比较:一项单中心队列研究

2026-09-290
OAAI
No evidence of cerebral microangiopathy in hereditary transthyretin amyloidosis: An MRI case-control study from an Italian Center

遗传性甲状腺素转运蛋白淀粉样变性中无脑微血管病变的证据:一项来自意大利中心的MRI病例对照研究

2026-09-210
OAAI
Plasma p-tau217 Versus p-tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease-Related Neurostructural Changes and Cognitive Function

血浆p-tau217与p-tau181在帕金森病中的比较:与阿尔茨海默病相关神经结构变化和认知功能的差异性关联

2026-06-150
OAAI
Neurological management and outcome measures in Fabry disease: consensus statements from the Italian Fabry disease neurological working group

法布里病的神经病学管理和结局指标:意大利法布里病神经病学工作组共识声明

2026-04-240
OAAI
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: the MIRAGE trial

瑞戈非尼与局部标准护理在不再适合局部区域治疗的患者中治疗WHO分级2-3级脑膜瘤的疗效比较:MIRAGE试验

2025-11-010
OAAI
REGORAFENIB VERSUS LOCAL STANDARD OF CARE IN PATIENTS WITH GRADE 2-3 MENINGIOMA NO LONGER ELIGIBLE FOR LOCO-REGIONAL TREATMENTS: THE MIRAGE TRIAL

瑞戈非尼 versus 局部标准护理:在不再适合局部区域治疗的患者中针对2-3级脑膜瘤的MIRAGE试验

2025-10-010
OA
Cognitive impairment in hereditary spherocytosis

遗传性球形红细胞增多症中的认知障碍

2025-08-150
OAAI